Editing a γ-globin repressor binding site restores fetal hemoglobin synthesis and corrects the sickle cell disease phenotype
Open accessThe DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Abstract
Editing the fetal γ-globin promoters in hematopoietic stem cells from sickle cell disease patients induces therapeutic γ-globin levels.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 LRF-binding site disruption induces γ-globin expression in HUDEP-2 cells. (A) Schematic representation of the β-globin locus on chromosome 11, depicting the hypersensitive sites of the locus control region (white boxes) and the HBE1, HBG2, HBG1, HBD, and HBB genes (colored boxes). The sequence of the HBG2 and HBG1 identical promoters (from −210 to −100 nucleotides upstream of the HBG TSS) is shown below. Black arrows indicate HPFH mutations described at HBG1 and/or HBG2 promoters, with the percentage of HbF in heterozygous carriers of HPFH mutations (42). The highest HbF levels were generally observed in individuals carrying SCD (*) or β-thalassemia mutations (**). LRF- and BCL11A-binding sites [as described in (11)] are highlighted by orange and green boxes, respectively. The −114/−102 13-bp HPFH deletion is indicated by an empty box. Red arrows indicate the gRNA cleavage sites. (B to E) Globin expression analyses were performed in mature erythroblasts differentiated from Cas9-GFP+ HUDEP-2 cells. Results are shown as means ± SEM of three to four independent experiments. (B) RT-qPCR quantification of (Gγ + Aγ)- and β-globin transcripts. mRNA levels were expressed as percentage of (γ + β) globins, after normalization to α-globin mRNA levels. (C) Representative flow cytometry plots showing the percentage of HbF+ cells. (D) RP-HPLC analysis of globin chains. β-Like globin expression was normalized to α-globin. Representative RP-HPLC chromatograms are reported together with the expression of γ-globin chains (in brackets). The ratio of α chains to non–α chains was similar between HBG-edited and control samples. (E) ChIP-qPCR analysis of H3K27Ac at HBB and HBG promoters in −197-edited HUDEP-2 cells and control AAVS1–edited samples (day 5 of differentiation, n = 3). ChIP was performed using an antibody against H3K27Ac and the corresponding control immunoglobulin G (IgG). ****P ≤ 0.0001, ***P ≤ 0.001, **P ≤ 0.01, and *P ≤ 0.05 (unpaired t test). SSC, side scatter. (F) ChIP-qPCR analysis of LRF at HBG promoters in −197-edited and control AAVS1–edited K562 cells (n = 2 biologically independent experiments). ChIP was performed using an antibody against LRF. Two different primer pairs were used to amplify the HBG promoters (A and B). KLF1 and DEFB122 served as positive and negative controls, respectively.](https://figures.cochat.ai/paper-figures/2fc47826f09a43f2bc36ffa2fad643e4/editing-a-globin-repressor-binding-site-restores-fetal-hemoglobin-synthesis-and-figure-1.jpg)


![Fig. 4 Editing efficiency in repopulating HSPCs. (A) Engraftment of human cells in NSG mice transplanted with untreated (UT) and edited mobilized healthy donor CD34+ cells (n = 4 mice for each group) 16 weeks after transplantation. Engraftment is represented as percentage of human CD45+ cells in the total murine and human CD45+ cell population, in bone marrow (BM), spleen, thymus, and blood. Values shown are means ± SEM; *P ≤ 0.05 versus untreated [one-way analysis of variance (ANOVA)]. (B) Editing efficiency in the bone marrow– and spleen-derived human CD45+ progeny of repopulating HSPCs, as evaluated by Sanger sequencing and TIDE analysis. The proportion of edited alleles in the input HSPC populations (〇: HSPCs cultured for 6 days in “HSPC medium”; □: BFU-E; △: CFU-GM) is indicated (input). Values shown are means ± SEM. Each data point represents an individual mouse. (C) Genome editing efficiency in the input populations and in bone marrow– and spleen-derived human CD45+ populations edited with the −197, −196, or −115 gRNAs, as evaluated by Sanger sequencing and TIDE analysis. The main events associated with MH-motifs are indicated. Values shown are means ± SEM (n = 4 mice per group). ***P ≤ 0.001, **P ≤ 0.01, and *P ≤ 0.05 versus input (unpaired t test).](https://figures.cochat.ai/paper-figures/c685de666b35421eaf08718520f7cc06/editing-a-globin-repressor-binding-site-restores-fetal-hemoglobin-synthesis-and-figure-4.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Disruption of BCL11A and ZBTB7A binding sites led to 30% to 40% g globin and 75% to 80% F-cells.27”
From Fetal hemoglobin in sickle cell anemia (2020) · cites this paper as [27]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Natural mutations and clustered regulary interspaced short palindromic repeat (CRISPR)-Cas9 disruption of the BCL11A and ZBTB7A binding sites are associated with a large effect on expression of the g-globin genes.12,21,27”
From Fetal hemoglobin in sickle cell anemia (2020) · cites this paper as [27]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Easy quantitative assessment of genome editing by sequence trace decomposition
Brinkman, E. K., Chen, T., Amendola, M., & van Steensel, B. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku936 · Cited by 2,390
Self-citationGUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases
Tsai, S. Q., Zheng, Z., Nguyen, N. T., Liebers, M., Topkar, V. V., Thapar, V., Wyvekens, N., Khayter, C., Iafrate, A. J., Le, L. P., et al. (2015) · Nature Biotechnology · doi:10.1038/nbt.3117 · Cited by 2,268 · cited 8×
“Library preparation was performed using the original adapters and primers according to previous work (27).”
BackgroundMethodInfluentialHaeussler, M., Schönig, K., Eckert, H., Eschstruth, A., Mianné, J., Renaud, J.-B., Schneider-Maunoury, S., Shkumatava, A., Teboul, L., Kent, J., et al. (2016) · Genome biology · doi:10.1186/s13059-016-1012-2 · Cited by 1,756
Self-citationCRISPR/Cas9 β-globin gene targeting in human haematopoietic stem cells
Dever, D. P., Bak, R. O., Reinisch, A., Camarena, J., Washington, G., Nicolas, C. E., Pavel-Dinu, M., Saxena, N., Wilkens, A. B., Mantri, S., et al. (2016) · Nature · doi:10.1038/nature20134 · Cited by 864
Inference of CRISPR Edits from Sanger Trace Data
Conant, D., Hsiau, T., Rossi, N., Oki, J., Maures, T., Waite, K., Yang, J., Joshi, S., Kelso, R., Holden, K., et al. (2022) · The CRISPR Journal · doi:10.1089/crispr.2021.0113 · Cited by 804
Gene therapy in a patient with sickle cell disease
Ribeil, J.-A., Hacein-Bey-Abina, S., Payen, E., Magnani, A., Semeraro, M., Magrin, E., Caccavelli, L., Neven, B., Bourget, P., El Nemer, W., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1609677 · Cited by 696
Self-citationGene Therapy in Patients with Transfusion-Dependent β-Thalassemia
Thompson, A. A., Walters, M. C., Kwiatkowski, J., Rasko, J. E. J., Ribeil, J.-A., Hongeng, S., Magrin, E., Schiller, G. J., Payen, E., Semeraro, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1705342 · Cited by 684
Self-citationEx vivo generation of fully mature human red blood cells from hematopoietic stem cells
Giarratana, M.-C., Kobari, L., Lapillonne, H., Chalmers, D., Kiger, L., Cynober, T., Marden, M. C., Wajcman, H., & Douay, L. (2005) · Nature Biotechnology · doi:10.1038/nbt1047 · Cited by 574
Targeted genome editing in human repopulating haematopoietic stem cells
Genovese, P., Schiroli, G., Escobar, G., Di Tomaso, T., Firrito, C., Calabria, A., Moi, D., Mazzieri, R., Bonini, C., Holmes, M. C., et al. (2014) · Nature · doi:10.1038/nature13420 · Cited by 555
Fetal hemoglobin in sickle cell anemia
Akinsheye, I., Alsultan, A., Solovieff, N., Ngo, D., Baldwin, C. T., Sebastiani, P., Chui, D. H. K., & Steinberg, M. H. (2011) · Blood · doi:10.1182/blood-2011-03-325258 · Cited by 553
Research works printed but not linked: 1
- 10.1016/j.ymthe.2018.10.008 · DOI · Paper page
Cited by
Chromothripsis as an on-target consequence of CRISPR–Cas9 genome editing
Leibowitz, M. L., Papathanasiou, S., Doerfler, P. A., Blaine, L. J., Sun, L., Yao, Y., Zhang, C.-Z., Weiss, M. J., & Pellman, D. (2021) · Nature Genetics · doi:10.1038/s41588-021-00838-7 · Cited by 583
Gene therapy using haematopoietic stem and progenitor cells
Ferrari, G., Thrasher, A. J., & Aiuti, A. (2021) · Nature Reviews Genetics · doi:10.1038/s41576-020-00298-5 · Cited by 254
Global marine microbial diversity and its potential in bioprospecting
Chen, J., Jia, Y., Sun, Y., Liu, K., Zhou, C., Liu, C., Li, D., Liu, G., Zhang, C., Yang, T., et al. (2024) · Nature · doi:10.1038/s41586-024-07891-2 · Cited by 190
Piel, F. B., Rees, D. C., DeBaun, M. R., Nnodu, O., Ranque, B., Thompson, A. A., Ware, R. E., Abboud, M. R., Abraham, A., Ambrose, E. E., et al. (2023) · The Lancet Haematology · doi:10.1016/s2352-3026(23)00096-0 · Cited by 177
Fetal hemoglobin in sickle cell anemia
Steinberg, M. H. (2020) · Blood · doi:10.1182/blood.2020007645 · Cited by 136
CRISPR/Cas9 gene editing for curing sickle cell disease
Park, S. H., & Bao, G. (2021) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2021.103060 · Cited by 145
The Promise and the Hope of Gene Therapy
Papanikolaou, E., & Bosio, A. (2021) · Frontiers in Genome Editing · doi:10.3389/fgeed.2021.618346 · Cited by 114
Base and Prime Editing Technologies for Blood Disorders
Antoniou, P., Miccio, A., & Brusson, M. (2021) · Frontiers in Genome Editing · doi:10.3389/fgeed.2021.618406 · Cited by 84
Self-citationPotent and uniform fetal hemoglobin induction via base editing
Mayuranathan, T., Newby, G. A., Feng, R., Yao, Y., Mayberry, K. D., Lazzarotto, C. R., Li, Y., Levine, R. M., Nimmagadda, N., Dempsey, E., et al. (2023) · Nature Genetics · doi:10.1038/s41588-023-01434-7 · Cited by 93
Therapeutic adenine base editing of human hematopoietic stem cells
Liao, J., Chen, S., Hsiao, S., Jiang, Y., Yang, Y., Zhang, Y., Wang, X., Lai, Y., Bauer, D. E., & Wu, Y. (2023) · Nature Communications · doi:10.1038/s41467-022-35508-7 · Cited by 94
Antoniou, P., Hardouin, G., Martinucci, P., Frati, G., Félix, T., Chalumeau, A., Fontana, L., Martin, J., Masson, C., Brusson, M., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34493-1 · Cited by 88
Self-citationFetal Hemoglobin in Sickle Hemoglobinopathies: High HbF Genotypes and Phenotypes
Steinberg, M. H. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9113782 · Cited by 89
Modulating gene regulation to treat genetic disorders
Matharu, N. K., & Ahituv, N. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0083-7 · Cited by 85
Fetal hemoglobin rescues ineffective erythropoiesis in sickle cell disease
Hoss, S. E., Cochet, S., Godard, A., Yan, H., Dussiot, M., Frati, G., Boutonnat-Faucher, B., Laurance, S., Renaud, O., Joseph, L., et al. (2020) · Haematologica · doi:10.3324/haematol.2020.265462 · Cited by 77
Self-citationDoerfler, P. A., Feng, R., Li, Y., Palmer, L. E., Porter, S. N., Bell, H. W., Crossley, M., Pruett‐Miller, S. M., Cheng, Y., & Weiss, M. J. (2021) · Nature Genetics · doi:10.1038/s41588-021-00904-0 · Cited by 69
The power and the promise of CRISPR/Cas9 genome editing for clinical application with gene therapy
Guo, N., Liu, J., Li, W., Ma, Y., & Fu, D. (2021) · Journal of Advanced Research · doi:10.1016/j.jare.2021.11.018 · Cited by 70
Hematopoietic Stem Cell Gene-Addition/Editing Therapy in Sickle Cell Disease
Germino-Watnick, P., Hinds, M., Le, A., Chu, R., Liu, X., & Uchida, N. (2022) · Cells · doi:10.3390/cells11111843 · Cited by 68
CRISPR-Cas9 to induce fetal hemoglobin for the treatment of sickle cell disease
Demirci, S., Leonard, A. K., Essawi, K., & Tisdale, J. F. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.09.010 · Cited by 61
Hardouin, G., Antoniou, P., Martinucci, P., Félix, T., Manceau, S., Joseph, L., Masson, C., Scaramuzza, S., Ferrari, G., Cavazzana, M., et al. (2022) · Blood · doi:10.1182/blood.2022016629 · Cited by 59
Self-citationZhang, M., Li, H., & Jin, Y. (2024) · Frontiers in Genetics · doi:10.3389/fgene.2024.1364742 · Cited by 73
Samuelson, C., Radtke, S., Zhu, H., Llewellyn, M. J., Fields, E., Cook, S. M., Huang, M.-L. W., Jerome, K. R., Kiem, H., & Humbert, O. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.10.008 · Cited by 54
Gene Therapy for Hemoglobinopathies
Leonard, A. K., Tisdale, J. F., & Bonner, M. A. (2022) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2022.03.008 · Cited by 55
CRISPRthripsis: The Risk of CRISPR/Cas9-induced Chromothripsis in Gene Therapy
Amendola, M., Brusson, M., & Miccio, A. (2022) · Stem Cells Translational Medicine · doi:10.1093/stcltm/szac064 · Cited by 51
Self-citationEnhanced HbF reactivation by multiplex mutagenesis of thalassemic CD34+ cells in vitro and in vivo
Psatha, N., Georgakopoulou, A., Li, C., Nandakumar, V., Georgolopoulos, G., Acosta, R., Paschoudi, K., Nelson, J. S., Chee, D. R., Athanasiadou, A., et al. (2021) · Blood · doi:10.1182/blood.2020010020 · Cited by 51
Sickle cell disease: progress towards combination drug therapy
Pace, B. S., Starlard‐Davenport, A., & Kutlar, A. (2021) · British Journal of Haematology · doi:10.1111/bjh.17312 · Cited by 57
In vivo base editing by a single i.v. vector injection for treatment of hemoglobinopathies
Li, C. L., Georgakopoulou, A., Newby, G. A., Everette, K. A., Nizamis, E., Paschoudi, K., Vlachaki, E., Gil, S., Anderson, A. K., Koob, T., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.162939 · Cited by 49
Cosenza, L. C., Gasparello, J., Romanini, N., Zurlo, M., Zuccato, C., Gambari, R., & Finotti, A. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.03.025 · Cited by 47
Gene Therapy and Gene Editing for β-Thalassemia
Christakopoulos, G. E., Telange, R., Yen, J. S., & Weiss, M. J. (2023) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2022.12.012 · Cited by 53
Revolutionising healing: Gene Editing's breakthrough against sickle cell disease
Dimitrievska, M., Bansal, D., Vitale, M., Strouboulis, J., Miccio, A., Nicolaides, K. H., Hoss, S. E., Shangaris, P., & Jackow, J. (2024) · Blood Reviews · doi:10.1016/j.blre.2024.101185 · Cited by 46
Self-citationGene Therapy of the Hemoglobinopathies
Kunz, J. B., & Kulozik, A. E. (2020) · HemaSphere · doi:10.1097/hs9.0000000000000479 · Cited by 42
Sickle Cell Disease: From Genetics to Curative Approaches
Hardouin, G., Magrin, E., Corsia, A., Cavazzana, M., Miccio, A., & Semeraro, M. (2023) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-120122-081037 · Cited by 40
Self-citationClinical genome editing to treat sickle cell disease—A brief update
Zarghamian, P., Klermund, J., & Cathomen, T. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2022.1065377 · Cited by 47
Hematopoietic Stem Cell-Targeted Gene-Addition and Gene-Editing Strategies for β-hemoglobinopathies
Drysdale, C. M., Nassehi, T., Gamer, J., Yapundich, M., Tisdale, J. F., & Uchida, N. (2021) · Cell stem cell · doi:10.1016/j.stem.2021.01.001 · Cited by 44
Current advances of CRISPR-Cas technology in cell therapy
Qiu, H.-Y., Ji, R.-J., & Zhang, Y. (2022) · Cell Insight · doi:10.1016/j.cellin.2022.100067 · Cited by 41
Structural basis for human ZBTB7A action at the fetal globin promoter
Yang, Y., Ren, R., Ly, L. C., Horton, J. R., Li, F., Quinlan, K. G. R., Crossley, M., Shi, Y., & Cheng, X. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109759 · Cited by 38
CRISPR/Cas-based gene editing in therapeutic strategies for beta-thalassemia
Zeng, S., Lei, S.-Y., Qu, C., Wang, Y., Teng, S., & Huang, P. C. (2023) · Human Genetics · doi:10.1007/s00439-023-02610-9 · Cited by 38
The p53 challenge of hematopoietic stem cell gene editing
Dorset, S. R., & Bak, R. O. (2023) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2023.06.003 · Cited by 33
Frati, G., Brusson, M., Sartre, G., Mlayah, B., Félix, T., Chalumeau, A., Antoniou, P., Hardouin, G., Concordet, J., Romano, O., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.07.015 · Cited by 37
Self-citationGenome Editing for β-Hemoglobinopathies: Advances and Challenges
Frati, G., & Miccio, A. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10030482 · Cited by 36
Self-citationGenome editing strategies for fetal hemoglobin induction in beta-hemoglobinopathies
Demirci, S., Leonard, A. K., & Tisdale, J. F. (2020) · Human Molecular Genetics · doi:10.1093/hmg/ddaa088 · Cited by 33
Genome editing approaches to β-hemoglobinopathies
Brusson, M., & Miccio, A. (2021) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2021.01.025 · Cited by 33
Self-citationDirect correction of haemoglobin E β-thalassaemia using base editors
Badat, M., Ejaz, A., Peng, H., Rice, S., Zhang, W., Hentges, L. D., Fisher, C. A., Denny, N., Schweßinger, R., Yasara, N., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37604-8 · Cited by 32
Genetic therapies for the first molecular disease
Doerfler, P. A., Sharma, A., Porter, J. S., Zheng, Y., Tisdale, J. F., & Weiss, M. J. (2021) · Journal of Clinical Investigation · doi:10.1172/jci146394 · Cited by 31
Editing outside the body: Ex vivo gene-modification for β-hemoglobinopathy cellular therapy
Rosanwo, T. O., & Bauer, D. E. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.10.002 · Cited by 35
Precision Editing as a Therapeutic Approach for β-Hemoglobinopathies
Paschoudi, K., Yannaki, E., & Psatha, N. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119527 · Cited by 34
CRISPR/Cas based gene editing: marking a new era in medical science
Prasad, K. M., George, A., Ravi, N. S., & Mohankumar, K. M. (2021) · Molecular Biology Reports · doi:10.1007/s11033-021-06479-7 · Cited by 35
An optimized SpCas9 high-fidelity variant for direct protein delivery
Pedrazzoli, E., Bianchi, A., Umbach, A., Amistadi, S., Brusson, M., Frati, G., Ciciani, M., Badowska, K. A., Arosio, D., Miccio, A., et al. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.03.007 · Cited by 27
Self-citationMaganti, H. B., Bailey, A. J.-M., Kirkham, A. M., Shorr, R., Pineault, N., & Allan, D. (2021) · Stem Cells Translational Medicine · doi:10.1002/sctm.20-0520 · Cited by 28
Alayoubi, A. M., Khawaji, Z. Y., Mohammed, M. A., & Mercier, F. (2023) · Annals of Hematology · doi:10.1007/s00277-023-05457-2 · Cited by 27
Brusson, M., Chalumeau, A., Martinucci, P., Romano, O., Félix, T., Poletti, V., Scaramuzza, S., Ramadier, S., Masson, C., Ferrari, G., et al. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2023.03.012 · Cited by 25
Self-citationRecent advancements in gene therapy for sickle cell disease and β-thalassemia
Li, L., & Mandal, P. K. (2024) · Frontiers in Hematology · doi:10.3389/frhem.2024.1468952 · Cited by 29
Cruz, L. J., Rezaei, S., Grosveld, F. G., Philipsen, S., & Eich, C. (2022) · Frontiers in Genome Editing · doi:10.3389/fgeed.2022.1030285 · Cited by 25
Genome editing of immune cells using CRISPR/Cas9
Kim, S., Hupperetz, C., Kim, C. H., & Kim, C. H. (2021) · BMB Reports · doi:10.5483/bmbrep.2021.54.1.245 · Cited by 26
Lessard, S., Rimmelé, P., Ling, H., Moran, K., Vieira, B. F., Lin, Y.-D., Rajani, G. M., Hong, V., Reik, A., Boismenu, R., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-74716-7 · Cited by 24
Venkatesan, V., Srinivasan, S., Babu, P., & Thangavel, S. (2020) · Molecular and Cellular Biology · doi:10.1128/mcb.00253-20 · Cited by 26
A Small Key for a Heavy Door: Genetic Therapies for the Treatment of Hemoglobinopathies
Zittersteijn, H. A., Harteveld, C. L., Klaver-Flores, S., Lankester, A. C., Hoeben, R. C., Staal, F. J. T., & Gonçalves, M. A. F. V. (2021) · Frontiers in Genome Editing · doi:10.3389/fgeed.2020.617780 · Cited by 24
Moiani, A., Letort, G., Lizot, S., Chalumeau, A., Foray, C., Félix, T., Clerre, D. L., Temburni, S., Hong, P. W.-P., Leduc, S., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-49353-3 · Cited by 21
Self-citationHan, Y., Tan, X., Jin, T., Zhao, S., Li, H., Zhang, W., Kurita, R., Nakamura, Y., Liu, J., Li, D., et al. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.174788 · Cited by 21
Katta, V., O’Keefe, K., Li, Y., Mayuranathan, T., Lazzarotto, C. R., Wood, R. K., Levine, R. M., Powers, A., Mayberry, K. D., Manquen, G., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.07.022 · Cited by 22
Multiplex base editing to protect from CD33 directed drugs for immune and gene therapy
Borot, F., Humbert, O., Ehmsen, J. T., Fields, E., Kohli, S., Radtke, S., Swing, K., Pande, D., Enstrom, M., Laszlo, G. S., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-59713-2 · Cited by 19
The Fetal-to-Adult Hemoglobin Switch — Mechanism and Therapy
Orkin, S. H. (2025) · New England Journal of Medicine · doi:10.1056/nejmra2405260 · Cited by 21
Effective therapies for sickle cell disease: are we there yet?
Crossley, M., Christakopoulos, G. E., & Weiss, M. J. (2022) · Trends in Genetics · doi:10.1016/j.tig.2022.07.003 · Cited by 22
Mingoia, M., Caria, C. A., Ye, L., Asunis, I., Marongiu, M. F., Manunza, L., Sollaino, M. C., Wang, J., Cabriolu, A., Kurita, R., et al. (2020) · British Journal of Haematology · doi:10.1111/bjh.17167 · Cited by 18
Combination of lentiviral and genome editing technologies for the treatment of sickle cell disease
Ramadier, S., Chalumeau, A., Félix, T., Othman, N., Aknoun, S., Casini, A., Maule, G., Masson, C., Cian, A. D., Frati, G., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.08.019 · Cited by 20
Self-citationChuan-ping, Z., Qiu, H.-Y., Zhang, C., Zhang, Y., Zhang, Y., Yin, H., Zhang, K., & Zhang, Y. (2023) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjad018 · Cited by 17
Gene Therapy for Hemoglobinopathies
Lidonnici, M. R., Scaramuzza, S., & Ferrari, G. (2023) · Human Gene Therapy · doi:10.1089/hum.2023.138 · Cited by 18
Recent Approaches for Manipulating Globin Gene Expression in Treating Hemoglobinopathies
Mussolino, C., & Strouboulis, J. (2021) · Frontiers in Genome Editing · doi:10.3389/fgeed.2021.618111 · Cited by 18
Ren, R., Horton, J. R., Chen, Q., Yang, J., Liu, B., Huang, Y., Blumenthal, R., Zhang, X., & Cheng, X. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.102885 · Cited by 16
Treating Sickle Cell Disease: Gene Therapy Approaches
Cavazzana, M., Corsia, A., Brusson, M., Miccio, A., & Semeraro, M. (2024) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-022124-022000 · Cited by 22
Self-citationFinotti, A., & Gambari, R. (2023) · Frontiers in Genome Editing · doi:10.3389/fgeed.2023.1204536 · Cited by 18
Genome editing for sickle cell disease: still time to correct?
Ceglie, G., Lecis, M., Canciani, G., Algeri, M., & Frati, G. (2023) · Frontiers in Pediatrics · doi:10.3389/fped.2023.1249275 · Cited by 16
Self-citationTreating genetic blood disorders in the era of CRISPR-mediated genome editing
Almotiri, A., Abogosh, A., Abdelfattah, A., Alowaisy, D., & Rodrigues, N. P. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.01.031 · Cited by 16
Newer Modalities and Updates in the Management of Sickle Cell Disease: A Systematic Review
Patel, Z. V., Prajjwal, P., Bethineedi, L. D., Patel, D., Khullar, K., Patel, H., Khatri, K., Marsool, M. D. M., Gadam, S., Aleti, S., et al. (2024) · Journal of Blood Medicine · doi:10.2147/jbm.s477507 · Cited by 13
Multiplex base editing of BCL11A regulatory elements to treat sickle cell disease
Fontana, L., Martinucci, P., Amistadi, S., Félix, T., Mombled, M., Tachtsidi, A., Corre, G., Chalumeau, A., Hardouin, G., Martin, J., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102376 · Cited by 15
Self-citationNucleic Acid Therapy for β-Thalassemia
d’Arqom, A. (2020) · Biologics · doi:10.2147/btt.s265767 · Cited by 16
Amistadi, S., Fontana, L., Magnoni, C., Félix, T., Charvin, M. K., Martinucci, P., Gautier, C., Gréau, L., Bessières, B., Antoniou, P., et al. (2025) · Nucleic Acids Research · doi:10.1093/nar/gkaf637 · Cited by 12
Self-citationGene Therapy as the New Frontier for Sickle Cell Disease
Garg, H., Tatiossian, K. J., Peppel, K., Kato, G. J., & Herzog, E. (2021) · Current Medicinal Chemistry · doi:10.2174/0929867328666210527092456 · Cited by 12
Lu, D., Xu, Z., Peng, Z., Yang, Y., Song, B., Xiong, Z., Ma, Z., Hongmei, G., Chen, B., Nakamura, Y., et al. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.881937 · Cited by 15
Gene Editing-Based Technologies for Beta-hemoglobinopathies Treatment
Rahimmanesh, I., Boshtam, M., Kouhpayeh, S., Khanahmad, H., Dabiri, A., Ahangarzadeh, S., Esmaeili, Y., Bidram, E., Vaseghi, G., Javanmard, S. H., et al. (2022) · Biology · doi:10.3390/biology11060862 · Cited by 16
Efficacy of “EnzActive mix” feed additive in piglet growing
Prudyus, Т. Y., & Віщур, О. І. (2022) · The Animal Biology · doi:10.15407/animbiol24.04.027 · Cited by 12
Starlard‐Davenport, A., Palani, C. D., Zhu, X., & Pace, B. S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26094192 · Cited by 10
Genome Editing for Rare Diseases
Pradhan, A., Kalin, T. V., & Kalinichenko, V. V. (2020) · Current Stem Cell Reports · doi:10.1007/s40778-020-00175-1 · Cited by 13
Forced enhancer-promoter rewiring to alter gene expression in animal models
Peslak, S. A., Demirci, S., Chandra, V., Ryu, B. Y., Bhardwaj, S. K., Jiang, J., Rupon, J. W., Throm, R. E., Uchida, N., Leonard, A. K., et al. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2023.01.016 · Cited by 11
Epigenetic Regulation of Erythropoiesis: From Developmental Programs to Therapeutic Targets
Vasiloudis, N.-I., Paschoudi, K., Beta, C., Georgolopoulos, G., & Psatha, N. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26136342 · Cited by 9
Babu, P., Azhagiri, M. K. K., Venkatesan, V., Magis, W., Prasad, K. M., Suresh, S., Pai, A. A., Marepally, S. K., Srivastava, A., Mohankumar, K. M., et al. (2024) · Stem Cell Research & Therapy · doi:10.1186/s13287-024-04117-0 · Cited by 9
Butt, H., Mandava, M., & Jacobsohn, D. A. (2025) · The CRISPR Journal · doi:10.1089/crispr.2024.0101 · Cited by 11
β-Hemoglobinopathies: The Test Bench for Genome Editing-Based Therapeutic Strategies
Barbarani, G., Łabędź, A., & Ronchi, A. E. (2020) · Frontiers in Genome Editing · doi:10.3389/fgeed.2020.571239 · Cited by 10
Chalumeau, A., Frati, G., Magrin, E., & Miccio, A. (2021) · BIO-PROTOCOL · doi:10.21769/bioprotoc.3899 · Cited by 8
Self-citationCosenza, L. C., Zuccato, C., Zurlo, M., Gambari, R., & Finotti, A. (2022) · Genes · doi:10.3390/genes13101727 · Cited by 9
Felder, A.-K., Tjalsma, S. J. D., Verhagen, H. J. M. P., Majied, R., Verstegen, M. J. A. M., Verheul, T. C. J., van Haren, J., Mohnani, R., Gremmen, R., Krijger, P. H. L., et al. (2025) · Blood · doi:10.1182/blood.2024028128 · Cited by 8
Treatment decision-making in sickle cell disease patients
Booth, A., Bonham, V. L., Porteus, M. H., & Ormond, K. E. (2021) · Journal of Community Genetics · doi:10.1007/s12687-021-00562-z · Cited by 8
Refractive index biosensor based on topological ring resonator
Liu, N., Wang, S., Lv, J., Lu, Y., & Zhang, J. (2023) · Optics Communications · doi:10.1016/j.optcom.2023.129542 · Cited by 8
CRISPR technology in human diseases
Feng, Q., Li, Q., Zhou, H., Wang, Z., Lin, C., Jiang, Z., Liu, T., & Wang, D. (2024) · MedComm · doi:10.1002/mco2.672 · Cited by 11
Wongborisuth, C., Innachai, P., Saisawang, C., Tubsuwan, A., Jearawiriyapaisarn, N., Kaewprommal, P., Piriyapongsa, J., Chiangjong, W., Anurathapan, U., Songdej, D., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-10791-8 · Cited by 7
Gnanapragasam, M. N., Planutis, A., Glassberg, J., & Bieker, J. J. (2023) · Scientific Reports · doi:10.1038/s41598-023-34805-5 · Cited by 7
Chandu, A., Ramalingam, S., Gowri, C. S. K. V., & Murugesan, S. (2025) · Life Sciences · doi:10.1016/j.lfs.2025.123536 · Cited by 7
In situ gene editing of hematopoietic stem cells via AAV-delivered CRISPR guide RNAs
Karimzadeh, A., Kim, R., Garcia, V., Florea, M., Peacker, B. L., Kobayashi, S., Watkins, D., Messemer, K. A., Zeng, J., Bauer, D. E., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2025016775 · Cited by 6
Liu, J., Park, K., Shen, Z., Ye, Y., Lee, E., Herman, R. A., Zhu, X., Lu, W., Nuhfer, J., Bassal, M. A., et al. (2024) · Transfusion Medicine Reviews · doi:10.1016/j.tmrv.2024.150861 · Cited by 5
SNA·SMNP·CBE system: A novel integrative strategy for β-hemoglobinopathies gene therapy
Cheng, H., Hui, W., Kang, H., Shi, Z., Liu, J., Wang, X., Qi, F., Mao, L., Ding, H., Hu, R., et al. (2024) · Nano Today · doi:10.1016/j.nantod.2024.102558 · Cited by 5
CRISPR–Cas9 Therapeutics in Early Clinical Development: Delivery and Molecular Diagnostics
Rutkowska, A., Strózik, T., Wasiak, T., Ciunowicz, D., Kapelan, N., Szczepaniak, N., Sosnowski, J., Goślińska, W., Bartkowiak, J., Budny-Lewandowska, A., et al. (2026) · Cells · doi:10.3390/cells15070644 · Cited by 5
Metadata
- Authors
- Weber, L., Frati, G., Felix, T., Hardouin, G., Casini, A., Wollenschlaeger, C., Meneghini, V., Masson, C., De Cian, A., Chalumeau, A., Mavilio, F., Amendola, M., Andre-Schmutz, I., Cereseto, A., El Nemer, W., Concordet, J.-P., Giovannangeli, C., Cavazzana, M., & Miccio, A.
- Affiliations
- Inserm (FR)
- Laboratory of chromatin and gene regulation during development, INSERM UMR1163, Paris, France.
- University of Trento (IT)
- Paris-Descartes Bioinformatics Platform, Imagine Institute, Paris 75015, France.
- INSERM U1154, CNRS UMR7196, Museum National d’Histoire Naturelle, Paris, France.
- University of Modena and Reggio Emilia (IT)
- Laboratory of Human Lymphohematopoiesis, INSERM UMR1163, Paris, France.
- Biologie Intégrée du Globule Rouge UMR_S1134, Inserm, Univ. Paris Diderot, Sorbonne Paris Cité, Univ. de la Réunion, Univ. des Antilles, Paris, France.
- Centre National de la Recherche Scientifique (FR)
- Hôpital Necker-Enfants Malades (FR)
- Corresponding author
- Weber, Leslie
- Frati, Giacomo
- Miccio, Annarita
- ORCID
- Venue
- Science Advances
- Published
- 2020-02-14
- Volume
- 6
- Issue
- 7
- Pages
- eaay9392
- ISSN
- 2375-2548 (ISSN-L)
- PMC
- PMC7015694
- OpenAlex
- W3006567544
- Semantic Scholar
- 52b26144b0ee0a8db71bd718acdc5bf17daaa068
- Cited by
- 140
- References
- 53
- Citations by year
- 2026: 11 · 2025: 19 · 2024: 20 · 2023: 26 · 2022: 19 · 2021: 30 · 2020: 15
- FWCI
- 11.65
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- Locations
- Science Advances (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by-nc)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion, cc-by-nc)
- Institutional Research Information System (Università degli Studi di Trento) (submittedVersion, cc-by-nc)
- HAL (submittedVersion)
- HAL (submittedVersion, other-oa)
- Funders
- European Research Council
- Agence Nationale de la Recherche
- Genopole
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Keywords
- sickle cell disease, fetal hemoglobin, CRISPR/Cas9 genome editing, hematopoietic stem and progenitor cells, xenotransplantation, promoter editing
- MeSH terms
- Gene Editing, Anemia, Sickle Cell, Binding Sites, Fetal Hemoglobin, Humans, Phenotype, beta-Thalassemia, beta-Globins, gamma-Globins, CRISPR-Cas Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.